Orchestra BioMed Holdings, Inc. Financial Ratios
OBIO|FY2025 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2025 SEC 10-K data.
Key Data Points
- Altman Z-Score -0.98 (distress zone, below 1.23 threshold)
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2025)
Return on Equity
-185.2%
Profit Margin
-2313.3%
Net Income / Revenue
Asset Turnover
0.02
Revenue / Total Assets
Equity Multiplier
3.48
Total Assets / Equity
Composite: -185.2% (reported: -185.2%)
Profitability
Liquidity
Current Ratio
6.45
Quick Ratio
6.43
Solvency
Interest Coverage
-
Efficiency
Asset Turnover
0.02
Inventory Turnover
0.66
Days Sales Outstanding
13 days
As of FY2025 · SEC 10-K Annual Filings · Last checked Jun 28, 2026
Earnings Quality
Accrual Ratio
-11.0%
-7.0pp YoY
Earnings are primarily supported by operating cash flow.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.